The present invention, pyridinoporphyrazine pyridinone derivatives (i) of formula (I) (wherein, there is a hydrogen atom or a (C 1 -C 4) alkyl group R1 the R2, - (CH 2) n - is a group B is a 4 or n = 0,1,2,3, where, (C 3 -C 5) cycloalkyl, or (C 1 -C 4) alkyl group, and B is ( There is a C 1 -C 4) alkoxy group are each independently, is that there is no group -CH- atom, carbon atom, heteroatom, during, Y, W Z, V and, V, W, Y and the ring Z is present, it is a six-membered ring or a five-membered, dotted line in the ring is intended to indicate that ring to be obtained is an aromatic ring, said ring is intended to include zero, one or two, heteroatoms well, or a group are each independently selected linear and hydrogen atoms (C 1 -C 4) alkyl group, R4 and R3 is the carbon to which they are bonded or different and may be the same taken together with the form a (C 3 -C 5) cycloalkyl group and integer equal to 4 or 1,2,3, m the R5, a hydrogen atom or a (C 1 -C 4) alkyl is a group R6 is and is - (CH 2) n -L group, where it is 3 or n = 0,1,2,, and aryl groups having 6 carbon atoms, L is a five-membered or a group selected from a saturated heterocyclic ring of seven-membered heteroaryl group, six-membered, five-membered or six-membered, the, on.) to form a heterocyclic ring together with the nitrogen to which the former is attached. It relates to the treatment used as inhibitors of the kinase activity of the receptor with FLT3 ligand and / or receptor with a (iii) PDGF ligand preparation and (ii) the derivative also present invention.本発明は、(i)式(I)のピリジノピリジノン誘導体(式中、R1は、水素原子または(C1-C4)アルキル基であり;R2は、-(CH2)n’-B基であり、ここでn’=0、1、2、3、または4であり、およびBは、(C3-C5)シクロアルキル基、(C1-C4)アルキル基、または(C1-C4)アルコキシ基であり;Y、Z、VおよびWは、それぞれ独立して、-CH-基、炭素原子、ヘテロ原子、まは原子がないことであり、V、W、YおよびZが存在する環は、五員または六員環とし、前記環の点線は得られる環が芳香環であることを示すものとし、前記環はヘテロ原子を0、1、または2個含むものとし;R3およびR4は、同一であっても異なっていてもよく、それぞれ独立して、水素原子および直鎖(C1-C4)アルキル基から選択される基であるか、これらが結合した炭素と一緒になって(C3-C5)シクロアルキル基を形成し;mは、1、2、3、または4に等しい整数であり;R5は、水素原子または(C1-C4)アルキル基であり;R6は、-(
